TP53 and B-cell chronic lymphocytic leukemia: This analysis confirmed previously reported associations, including increased sensitivity of TP53 wild-type samples to fludarabine, doxorubicin, and nutlin-3 (Fig. 2b) and increased sensitivity of CLL samples with unmutated IGHV status (U-CLL) to BCRi, e.g., spebrutinib, R406, and ibrutinib, as well as two checkpoint kinase (CHEK) inhibitors (Fig. 2c) that we recently reported to target the BCR [37].